Page 85 - 《中国药房》2025年4期
P. 85

·药物与临床·


          基于药动学/药效学理论和蒙特卡罗模拟的硫酸黏菌素给药方案

          效果评价
                        Δ

                                          2
                 1*
                          1
          马颖超 ,吴 瑕 ,王永静 ,顾建军 ,杨秀岭 (1.河北医科大学第二医院药学部,石家庄 050061;2.河北医科
                                                   1 #
                                  1
          大学第二医院心脏外科,石家庄 050061)
          中图分类号  R978.1;R969.1      文献标志码  A      文章编号  1001-0408(2025)04-0459-05
          DOI  10.6039/j.issn.1001-0408.2025.04.12

          摘  要  目的  基于药动学(PK)/药效学(PD)理论和蒙特卡罗模拟(MCS)评价5种硫酸黏菌素给药方案用于常见革兰氏阴性菌
          感染的治疗效果。方法  收集2023年中国细菌耐药监测网中硫酸黏菌素对鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌、大肠埃
          希菌、阴沟肠杆菌的最小抑菌浓度(MIC)数据,以游离浓度24 h药时曲线下面积与MIC的比值(fAUC0-24 h/MIC)≥15为目标靶值进
          行MCS,获得5种硫酸黏菌素给药方案在不同MIC下达到目标靶值的达标概率(PTA),并进一步计算各给药方案在特定细菌群体
          中的预期群体PTA,即累积反应分数(CFR),以评价5种硫酸黏菌素给药方案的治疗效果。结果  当细菌MIC≤0.5 μg/mL时,硫酸
          黏菌素所有给药方案(50万单位、q12 h,50万单位、q8 h,75万单位、q12 h,75万单位、q8 h,100万单位、q12 h)的PTA均超过90%;
          当MIC=1 μg/mL时,75万单位、q8 h的给药方案用于鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌、大肠埃希菌、阴沟肠杆菌,以
          及100万单位、q12 h的给药方案用于除铜绿假单胞菌外其余4种细菌的PTA仍可达90%以上;当MIC≥2 μg/mL时,硫酸黏菌素
          上述5种给药方案的PTA均低于90%。对于大肠埃希菌感染,仅50万单位、q12 h给药方案的CFR低于90%;对于肺炎克雷伯菌感
          染,仅75万单位、q8 h和100万单位、q12 h给药方案的CFR大于90%;对于其他3种细菌,硫酸黏菌素上述5种给药方案的CFR均
          低于90%。结论  当革兰氏阴性菌MIC≤0.5 µg/mL时,可选择硫酸黏菌素常规剂量治疗;当MIC=1 µg/mL时,则需要增加给药剂
          量或给药频次。经验性治疗时,除大肠埃希菌外,对于其余4种细菌感染,均需使用超说明书剂量。
          关键词  硫酸黏菌素;革兰氏阴性菌;药动学/药效学理论;蒙特卡罗模拟

          Evaluation of colistin sulfate administration regimen based on PK/PD theory and Monte Carlo simulation

          MA Yingchao ,WU Xia ,WANG Yongjing ,GU Jianjun ,YANG Xiuling(1.  Dept.  of  Pharmacy,  the  Second
                               1
                                                1
                                                                            1
                                                            2
                      1
          Hospital  of  Hebei  Medical  University,  Shijiazhuang  050061,  China;2.  Dept.  of  Cardiac  Surgery,  the  Second
          Hospital of Hebei Medical University, Shijiazhuang 050061, China)
          ABSTRACT   OBJECTIVE  To  evaluate  the  therapeutic  efficacy  of  5  regimens  of  colistin  sulfate  for  common  Gram-negative
          bacilli  infection  based  on  pharmacokinetics (PK)/pharmacodynamics (PD)  theory  and  Monte  Carlo  simulation.  METHODS
          Minimal  inhibitory  concentration (MIC)  data  of  colistin  sulfate  against  Acinetobacter  baumannii,  Pseudomonas  aeruginosa,
          Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae in 2023 were collected from the China Antimicrobial Resistance
          Surveillance System. Monte Carlo simulation was conducted with the ratio of the area under the concentration-time curve from 0 to
          24 hours in the unbound state to the MIC (fAUC0-24 h/MIC) ≥15 as the target value, the probabilities of target attainment (PTA) of
          5  regimens  of  colistin  sulfate  to  achieve  the  target  ratio  were  obtained  at  different  MIC;  and  the  expected  population  PTA,
          specifically  the  cumulative  fraction  of  response (CFR),  for  each  regimen  within  a  specific  bacterial  population  was  further
          calculated,  to  evaluate  the  therapeutic  efficacy  of  the  five  colistin  sulfate  regimens.  RESULTS  When  bacterial  MIC≤0.5  µg/mL,
          PTA of all colistin sulfate regimens (500 000 IU, q12 h; 500 000 IU, q8 h; 750 000 IU, q12 h; 750 000 IU, q8 h; 1 000 000
                                                             IU,  q12  h)  were  all  more  than  90%.  When  bacterial  MIC=1

             Δ 基金项目 河北省医学科学研究课题(No.20210257)                 µg/mL,  PTA  for  regimen  (750  000  IU,  q8  h)  against
             *第一作者 主管药师,硕士。研究方向:临床药学。E-mail:                 A.  baumannii,  K.  pneumoniae,  P.  aeruginosa,  E.  coli  and
          Mayingchao2008@sina.com
                                                             E.  cloacae,  and  for  regimen (1  000  000  IU,  q12  h)  against
             # 通信作者 主任药师,博士。研究方向:临床药学、医院药学。
          E-mail:yxl20031109@sina.com                        the  other  four  bacterial  species (excluding  P.  aeruginosa)


          中国药房  2025年第36卷第4期                                                 China Pharmacy  2025 Vol. 36  No. 4    · 459 ·
   80   81   82   83   84   85   86   87   88   89   90